Project: A novel, topical drug for treatment of diabetic foot infections (DFI)
We want to provide solid evidence of the clinical efficacy of LTX-109 in treatment of infections in diabetic foot ulcers, which is a debilitating medical condition with a large unmet need. The effect of this novel, topical antimicrobial drug will be demonstrated in a Phase II proof-of-concept study in patients with mild diabetic foot ulcers. The drug development will be accomplished in collaboration with other European SMEs.
| Acronym | CureDFI (Reference Number: 9146) |
| Duration | 01/10/2014 - 01/03/2016 |
| Project Topic | Biological Sciences / Technologies |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 1 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 19687 | Lytix Biopharma AS | Coordinator | Norway |
| 19688 | Smerud Medical Research UK Ltd | Partner | United Kingdom |
| 19689 | MedPharm Ltd | Partner | United Kingdom |
| 19690 | CTC Clinical Trial Consultants AB | Partner | Sweden |